Cyclopharm's US market advancements

Cyclopharm (ASX:CYC) is making significant strides in the United States market with its flagship product, Technegas™. Following a successful reimbursement approval from the Centers for Medicare and Medicaid Services (CMS), Cyclopharm has seen an 82% increase in pipeline opportunities. As of July 2024, Technegas is installed in nine US sites with numerous contracts indicating further expansion.

Cyclopharm's strategic and financial outlook

Cyclopharm has effectively capitalized on the US market opportunities for Technegas, driven by CMS reimbursement approval. The company's strategic plan includes expanding Technegas applications beyond pulmonary embolism to other respiratory conditions, supported by clinical trials. Cyclopharm maintains a strong global presence with Technegas sales in 64 countries and boasts a robust financial position with $27.56 million in net cash. Through its 'Beyond PE' initiative and strategic partnerships, Cyclopharm aims for 300 Technegas installations in the US by 2025, while continuing to enhance its educational and service infrastructure to support this growth.

Insights from Cyclopharm's leadership

We are thrilled with the progress and acceptance of Technegas in the United States, which has been greatly enhanced by the CMS reimbursement approval. This milestone marks a significant step forward in expanding our market reach and realizing the potential of Technegas for a broader range of respiratory diseases.